Table 1 Immunoexpression of HER-2/neu and p53 in relation to clinicopathological parameters of breast carcinoma

Type of breast tissue

Normal

20 (17.39)

0 (0)

20 (100)

0 (0)

20 (100)

Benign (fibroadenoma)

25 (21.74)

0 (0)

25 (100)

0 (0)

25 (100)

Malignant

70 (60.87)

33 (47.14)

37 (52.86)

25 (35.71)

45 (64.29)

P < 0.05

P < 0.05

Histological type

Lobular carcinomas

8 (11.43)

1 (12.50)

7 (87.50)

2 (25)

6 (75)

Ductal carcinomas including:

62 (88.57)

32 (51.61)

30 (48.39)

23 (37.10)

39 (62.90)

P < 0.05

P > 0.05

Pure IDC

47 (67.14)

19 (40.43)

28 (59.57)

18 (38.30)

29 (61.70)

IDC + DCIS

9 (12.86)

7 (77.68)

2 (22.22)

2 (22.22)

7 (77.78)

IDC+ Paget's

2 (2.86)

2 (100)

0 (0)

1 (50)

1 (50)

DCIS + Paget's

1 (1.44)

1 (100)

0 (0)

1 (100)

0 (0)

Pure DCIS

3 (4.29)

3 (100)

0 (0)

1 (33.33)

2 (66.67)

P < 0.05

P > 0.05

Tumor grade

Well-moderately differentiated (I and II)

14 (20)

7 (50)

7 (50)

2 (14.29)

12 (85.71)

Poorly differentiated (III)

56 (80)

26 (46.43)

30 (53.57)

23 (41.07)

33 (58.93)

P > 0.05, R > 0.3

P > 0.05,

R > 0.3

Tumor size

Tis

4 (5.71)

4 (100)

0 (0)

2 (50)

2 (50)

T1 (≤

2 cm)

7 (10)

2 (28.57)

5 (71.43)

2 (28.57)

5 (71.43)

T2 (2 > -5 cm)

38 (54.29)

13 (34.21)

25 (65.79)

6 (15.79)

32 (84.21)

T3 (> 5 cm)

19 (27.14)

13 (68.42)

6 (31.58)

14 (73.68)

5 (26.32)

T4 (anyT+other)

2 (2.86)

1 (50)

1 (50)

1 (50)

1 (50)

P < 0.05

R < 0.3

P < 0.05

R > 0.3

Axillary lymph nodes1

Negative

27 (48.21)

6 (22.22)

2 (77.78)

7 (25.93)

20 (74.07)

Positive

29 (51.79)

19 (65.52)

10 (34.48)

17 (58.62)

12 (41.38)

P < 0.05

P < 0.05

Age of the patient

< 35 years

19 (27.14)

12 (63.16)

7 (36.84)

8 (42.11)

11 (57.89)

> 35years

51 (72.86)

21 (41.18)

30 (58.82)

17 (33.33)

34 (66.67)

P > 0.05

P > 0.05

Tumor recurrence

Primary

51 (72.86)

17 (33.33)

34 (66.67)

13 (25.49)

38 (74.51)

Recurrent

19 (27.14)

16 (84.21)

3 (15.79)

12 (63.16)

7 (36.84)

P < 0.05

P < 0.05